TabletsTablets
Schedule H (Prescription Required)Hormonal OncologyCode: 788

Anastrozole Tablets 1mg

Generic Formulation:Anastrozole Tablets IP 1mg
Pack Size:10's
Common Commercial Brand Equivalents:Market reference only
Jan Aushadhi MRP
₹73.13
Brand Estimate*
₹528.5
Estimated Savings:₹455.37 (86% saved)
Find a Kendra Near You
*Statutory price across 21,118 listed Kendras
Clinical InformationReport Error

Clinical Overview

Anastrozole Tablets (1mg) is a potent and selective non-steroidal third-generation aromatase inhibitor on the WHO Model List of Essential Medicines. It inhibits aromatase (CYP19A1) by competitive binding, suppressing serum estradiol concentrations by >80-85% in postmenopausal women without affecting cortisol, aldosterone, or thyroxine synthesis. Indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer and first-line treatment of locally advanced or metastatic HR+ breast cancer.

Active Pharmaceutical Ingredients

AI-assistedClinical summary synthesized from pharmacopoeial references (CDSCO, WHO EML, IP/BP/USP). Not clinician-reviewed. Drug code 788.Report inaccuracy

Usage Guidelines

Take orally 1 mg once daily with water, with or without food. Duration is typically 5 years.

General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.

Possible Side Effects

Common: Hot flushes, arthralgia, arthritis, joint stiffness, asthenia, bone pain, osteoporosis, nausea. Rare/Severe: Bone fractures, ischemic cardiovascular events, and thromboembolism.

*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.

Precautions & Warnings

Contraindicated in premenopausal women and pregnancy. Causes accelerated bone demineralization; monitor bone mineral density with DEXA scans and initiate bisphosphonates if T-score drops. Concomitant tamoxifen reduces anastrozole plasma levels and should be avoided.

Schedule H (Prescription Required)

This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.

Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.